Combination Therapy with Nateglinide and Telmisartan Ameliorates Insulin Resistance in Zucker Fatty Rats by Suppressing Advanced Glycation End Product Receptor Axis

Abstract

Advanced glycation end products (AGEs) and their receptor (RAGE) have been shown to play a role in insulin resistance. We have previously shown that combination therapy with nateglinide (NAT) and telmisartan (TEL) improves postprandial metabolic derangements in Zucker fatty (ZF) rats, an animal model of insulin resistance with obesity. However, effects of combination therapy on insulin resistance remain unknown. We investigated here whether combination therapy with TEL and NAT could ameliorate insulin resistance in ZF rats by suppressing AGE-RAGE axis. NAT and/or TEL inhibited insulin receptor substrate-1 (IRS-1) serine phosphorylations at 307 and 636/639 residues in the liver of ZF rats. Further, combination therapy with NAT and TEL, but not each monotherapy alone, significantly restored the decrease in hepatic IRS-1 tyrosine phosphorylation in these animals. In addition, serum levels of AGEs, RAGE expression levels in the liver and hepatic AGE-RAGE index were decreased in NAT plus TEL-treated ZF rats. The present study suggests that combination therapy with NAT and TEL could ameliorate insulin resistance in ZF rats by suppressing the AGE-RAGE axis in the liver.

References

• 1 Yamagishi S, Nakamura K, Matsui T. Pharmacol Res. 2009;  60 174-178
• 2 Tahara N, Yamagishi S, Matsui T, Takeuchi M, Nitta Y, Kodama N, Mizoguchi M, Imaizumi T. Cardiovasc Ther. 2010;  July 7 [Epub ahead of print]
• 3 Unoki H, Yamagishi S. Curr Pharm Des. 2008;  14 987-989
• 4 Yoshida T, Yamagishi S, Matsui T, Nakamura K, Ueno T, Takeuchi M, Sata M. J Int Med Res. 2008;  36 237-243
• 5 Kajioka T, Miura K, Kitahara Y, Yamagishi S. Horm Metab Res. 2007;  39 889-893
• 6 Ozes ON, Akca H, Mayo LD, Gustin JA, Maehama T, Dixon JE, Donner DB. Proc Natl Acad Sci USA. 2001;  98 4640-4645
• 7 Unoki H, Yamagishi S, Takeuchi M, Bujo H, Saito Y. Protein Pep Lett. 2010;  17 1177-1182
• 8 Aguirre V, Werner ED, Giraud J, Lee YH, Shoelson SE, White MF. J Biol Chem. 2002;  277 1531-1537
• 9 Werner ED, Lee J, Hansen L, Yuan M, Shoelson SE. J Biol Chem. 2004;  279 35298-35305
• 10 Yoshida T, Yamagishi S, Nakamura K, Matsui T, Imaizumi T, Takeuchi M, Koga H, Ueno T, Sata M. Diabetologia. 2006;  49 3094-3099
• 11 Park L, Raman KG, Lee KJ, Lu Y, Ferran Jr LJ, Chow WS, Stern D, Schmidt AM. Nat Med. 1998;  4 1025-1031
• 12 Kitahara Y, Takeuchi M, Miura K, Mine T, Matsui T, Yamagishi S. Clin Exp Med. 2008;  8 175-177
• 13 Morita Y, Ueno T, Sasaki N, Tateishi Y, Nagata E, Kage M, Sata M. Hepatogastroenterology. 2005;  52 1338-1343
• 14 Georgescu EF, Ionescu R, Niculescu M, Mogoanta L, Vancica L. World J Gastroenterol. 2009;  15 942-954

Notice:

This article was changed according to the following erratum on November 16th, 2010: One of the authors' name is misspelt. The correct name is M. Takeuchi.

Correspondence